Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

SapC-DOPS technology: New way to image glioblastoma multiforme tumors

SapC-DOPS technology: New way to image glioblastoma multiforme tumors

Research team identifies specific genes that may lead to improved survival of glioblastoma

Research team identifies specific genes that may lead to improved survival of glioblastoma

Biochemists identify protein that can slow down growth of brain tumors in mice

Biochemists identify protein that can slow down growth of brain tumors in mice

Study reveals how ovarian cancer metabolism changes between early, late stages

Study reveals how ovarian cancer metabolism changes between early, late stages

Novogen partners with Genea Biocells to accelerate testing for neurodegenerative diseases

Novogen partners with Genea Biocells to accelerate testing for neurodegenerative diseases

UCSD neurosurgeons study MRI-guided biopsy approach to diagnose patients with brain cancer

UCSD neurosurgeons study MRI-guided biopsy approach to diagnose patients with brain cancer

Human fat: A Trojan horse to fight brain cancer?

Human fat: A Trojan horse to fight brain cancer?

Researchers create tiny, biodegradable nanoparticles that carry DNA to brain cancer cells

Researchers create tiny, biodegradable nanoparticles that carry DNA to brain cancer cells

Researchers develop class of drugs to lessen impact of Alzheimer's, Parkinson's

Researchers develop class of drugs to lessen impact of Alzheimer's, Parkinson's

TGen honors two philanthropists for supporting TGen's research on brain, colon and prostate cancer

TGen honors two philanthropists for supporting TGen's research on brain, colon and prostate cancer

Longer looks: Vermont's single payer system; Nevada's cancer cluster; the toll of dementia on a family

Longer looks: Vermont's single payer system; Nevada's cancer cluster; the toll of dementia on a family

Comprehensive genomic analysis of low-grade brain tumors sorts into three categories

Comprehensive genomic analysis of low-grade brain tumors sorts into three categories

Multiple genomic data could help improve studies of association between genes and disease

Multiple genomic data could help improve studies of association between genes and disease

Research shows blocking DNA repair improves radiation therapy for glioblastomas

Research shows blocking DNA repair improves radiation therapy for glioblastomas

Researchers find new molecular targets for aggressive brain tumor

Researchers find new molecular targets for aggressive brain tumor

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

Evotec signs research collaboration and licensing deal with Debiopharm Group

Evotec signs research collaboration and licensing deal with Debiopharm Group

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.